DRL's USA facility gets 2 observations from USFDA
Dr Reddy's Laboratories (DRL) said that US Food and Drug Administration (USFDA) had conducted a GMP inspection at its API Middleburgh facility in New York, USA from 12th May to 16th May 2025.
The USFDA completed aforementioned inspection and issued form-483 with two observations.Hyderabad-based Dr. Reddys Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.
The company reported a consolidated net profit of Rs 1,594 crore for the quarter ended March 2025 (Q4FY25), marking a 22% year-on-year increase from Rs 1,307 crore in the same period last year. Revenue from operations rose 20% year-on-year to Rs 8,506 crore, compared to Rs 7,083 crore in Q4FY24.
The counter shed 0.35% to end at Rs 1,230.50 on Friday, 16 May 2025.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 19 2025 | 8:32 AM IST